Karp Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Karp Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-250	Closed	-$18K	–	382
2018 Q4	$18K	Sell	250 -39,495	-99%	-$3.18M	0.01%	227
2018 Q3	$3.81M	Buy	+39,745	New	+$3.85M	1.31%	28

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Karp Capital Management's XBI Position: Q1 2019 in Review

Karp Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2019, closing a stake of 250 shares — an estimated $18K sold.

Karp Capital Management first reported a position in XBI in Q3 2018 and held it in 2 quarters. The position peaked at $3.81M in Q3 2018. 451 funds tracked by Wall St. Rank hold XBI as of Q1 2019.

Karp Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2019 after selling out during the quarter.
Karp Capital Management sold 250 State Street SPDR S&P Biotech ETF shares in Q1 2019, an estimated $18K.
Karp Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2018 and held it in 2 quarters.
Karp Capital Management's State Street SPDR S&P Biotech ETF position peaked at $3.81M in Q3 2018.
451 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2019.

Based on Karp Capital Management's 13F filing for Q1 2019, filed 7 May 2019.